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Impact of Global Geographic Region on Time in Therapeutic Range on
Warfarin Anticoagulant Therapy: Data From the ROCKET AF Clinical Trial
Daniel E. Singer, MD; Anne S. Hellkamp, MS; Jonathan P. Piccini, MD; Kenneth W. Mahaffey, MD; Yuliya Lokhnygina, PhD;
Guohua Pan, PhD; Jonathan L. Halperin, MD; Richard C. Becker, MD; Günter Breithardt, MD; Graeme J. Hankey, MD; Werner Hacke, MD;
Christopher C. Nessel, MD; Manesh R. Patel, MD; Robert M. Califf, MD; Keith A. A. Fox, MB, ChB; ROCKET AF Investigators
Background-—Vitamin K antagonist (VKA) therapy remains the most common method of stroke prevention in patients with atrial
ﬁbrillation. Time in therapeutic range (TTR) is a widely cited measure of the quality of VKA therapy. We sought to identify factors
associated with TTR in a large, international clinical trial.
Methods and Results-—TTR (international normalized ratio [INR] 2.0 to 3.0) was determined using standard linear interpolation in
patients randomized to warfarin in the ROCKET AF trial. Factors associated with TTR at the individual patient level (i-TTR) were
determined via multivariable linear regression. Among 6983 patients taking warfarin, recruited from 45 countries grouped into 7
regions, the mean i-TTR was 55.2% (SD 21.3%) and the median i-TTR was 57.9% (interquartile range 43.0% to 70.6%). The mean
time with INR <2 was 29.1% and the mean time with an INR >3 was 15.7%. While multiple clinical features were associated with
i-TTR, dominant determinants were previous warfarin use (mean i-TTR of 61.1% for warfarin-experienced versus 47.4% in VKA-naïve
patients) and geographic region where patients were managed (mean i-TTR varied from 64.1% to 35.9%). These effects persisted in
multivariable analysis. Regions with the lowest i-TTRs had INR distributions shifted toward lower INR values and had longer inter-
INR test intervals.
Conclusions-—Independent of patient clinical features, the regional location of medical care is a dominant determinant of variation
in i-TTR in global studies of warfarin. Regional differences in mean i-TTR are heavily inﬂuenced by subtherapeutic INR values and are
associated with reduced frequency of INR testing.
Clinical Trial Registration-—URL: ClinicalTrials.gov. Unique identiﬁer: NCT00403767. ( J Am Heart Assoc. 2013;2:e000067 doi:
10.1161/JAHA.112.000067)
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B oth the efﬁcacy and safety of warfarin anticoagulation inpatients with atrial ﬁbrillation (AF) are strongly depen-
dent on the intensity of anticoagulation measured as the
international normalized ratio (INR). The risk of ischemic
stroke increases with INR levels <1.8, and the risk of
intracranial hemorrhage increases sharply at INR levels >3.5.1
These ﬁndings support the standard “therapeutic” INR range
of 2.0 to 3.0 for atrial ﬁbrillation.2–4 A commonly used
summary of the quality of warfarin anticoagulation is the
linearly interpolated percent time in the therapeutic range
(TTR).5–7 While many patient- and system-level variables have
been demonstrated to affect the INR, and there have been
analyses of variation of average TTR at the institutional or
geographic level,8,9 there are relatively few large studies
assessing the impact of patient features on TTR at the level of
the individual patient.10 In the current study, we explored
individual and regional determinants of TTR among patients
randomly allocated to warfarin in the global ROCKET AF
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Compared with vitamin K antagonism for prevention of stroke
and Embolism Trial in Atrial Fibrillation) double-blind trial of
rivaroxaban versus adjusted-dose warfarin in patients with
atrial ﬁbrillation.11,12
Methods
The design, conduct, and main results of the ROCKET AF
trial have been presented previously.11,12 In brief, rivarox-
aban (20 mg daily; 15 mg daily in patients with creatinine
clearance of 30 to 49 mL/min) was compared with
adjusted-dose warfarin (INR point target of 2.5, INR range
2.0 to 3.0) for the prevention of stroke or systemic
embolism. Patients with electrocardiographically docu-
mented nonvalvular atrial ﬁbrillation at moderate to high
risk of stroke were recruited at 1178 participating sites in
45 countries. Elevated risk was indicated by a history of
stroke, transient ischemic attack (TIA), or systemic embolism
or ≥2 of the following: heart failure or left ventricular
ejection fraction ≤35%, hypertension, age ≥75 years, or
diabetes mellitus (CHADS2 score ≥2).13 The proportion of
patients without prior ischemic stroke, TIA, or systemic
embolism and ≤2 risk factors was limited to 10% of the
cohort by region; the remainder required either prior
thromboembolism or ≥3 risk factors. Investigators were
chosen on the basis of performance in clinical trials and
access to large clinical practices that included patients with
atrial ﬁbrillation. We do not have comprehensive information
on recruiting physicians’ specialty status. Warfarin dosing
was managed by local physicians based on INR values
generated by a standard point-of-care device (HemoSense,
San Jose, CA). While physicians were reminded about the
INR target of the trial and the need for monthly INR tests
even when patients’ anticoagulation status was stable,14 the
study did not provide speciﬁc treatment algorithms for
anticoagulation management. Patients with <6 weeks of
exposure to vitamin K antagonist (VKA) medication immedi-
ately before entry into the trial were considered VKA naïve.
Statistical Analysis
For the current analyses, patients were included if they had
been assigned to warfarin in the ROCKET AF trial and took ≥1
dose of warfarin and had ≥1 INR test. Daily INR values between
tests were imputed using the Rosendaal technique,6 and
individual patient-level TTR (i-TTR) was calculated as the
proportion of daily values within a strict range of INR 2.0 to
3.0. This included time during the initiation of warfarin at the
start of the trial and after temporary interruptions but did not
include time during temporary interruptions of ≥7 days or any
time after permanent discontinuation. Only 0.18% of inter-INR
test intervals were >8 weeks. Univariable relationships
between baseline variables and i-TTR were assessed with
single-predictor linear regression models. A multivariable
model was developed using multiple linear regression in which
a set of independent predictors was chosen in stepwise fashion
from a set of candidate predictors. These candidates were age,
sex, geographic region, body mass index, systolic and diastolic
blood pressures, atrial ﬁbrillation type, hypertension, diabetes,
prior stroke or TIA, coronary artery disease, chronic obstructive
pulmonary disease, peripheral artery disease, prior gastroin-
testinal bleed, liver disease, alcohol consumption in the past
12 months, CHADS2 score, estimated glomerular ﬁltration rate
(Modiﬁcation of Diet in Renal Disease equation),15 hemoglobin,
patient medications, and type of prior VKA experience. Only
variable values at entry to the study were used. Multivariable
models were developed both with and without a random effect
for center; we report only the results for the models without a
random effect for center, because both modeling approaches
produced highly similar results. Regional and country mean
i-TTRs were unweighted averages of i-TTR values for all
individuals within the given region or country, respectively.
The relationship between geographic region and i-TTR was
further characterized using linear regression models with
region as the only predictor within subgroups deﬁned by prior
VKA experience, both for i-TTR and for i-TTR excluding the ﬁrst
90 days of warfarin therapy. For the current analysis, we
grouped the countries involved in the ROCKET AF trial into the
following regions: East Asia (China, Hong Kong, Korea,
Malaysia, Philippines, Singapore, Thailand, and Taiwan); India;
Eastern Europe (Bulgaria, Czech Republic, Greece, Hungary,
Lithuania, Poland, Romania, Russia, Turkey, and Ukraine);
Western Europe and similar (Western Europe/similar: Austra-
lia, Austria, Belgium, Switzerland, Germany, Denmark, Spain,
Finland, France, Great Britain, Israel, Italy, Netherlands,
Norway, New Zealand, and Sweden); South Africa; Latin
America (Argentina, Brazil, Chile, Colombia, Mexico, Peru, and
Venezuela); and Canada/United States. These regional group-
ings were modiﬁed from those used in the primary trial report
to provide more cultural and ethnic homogeneity.12 Analyses
done with the original regional groupings reproduced the
same patterns of regional effect on average i-TTR although the
overall R2 values for the multivariable models were modestly
reduced (data not shown). We did not include terms for both
region and race in the same multivariable models because the
2 were almost completely collinear. We summarize stroke risk
using the CHADS2 score.
13 Statistical signiﬁcance of differ-
ences in the width of distributions of INR values across
regions was assessed using the Miller jackknife technique.16
Human Subjects
All individuals enrolled in the study gave informed consent. All
appropriate national regulatory authorities and ethics
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committees at participating centers approved the study. An
international executive committee designed the study and
takes responsibility for the accuracy and completeness of all
analyses.
Results
Baseline Patient Features
The ROCKET AF trial recruited atrial ﬁbrillation patients at high
risk for ischemic stroke. In the subpopulation (n=6983)
included in the current analysis, the mean age was 71 years
(median 73 years), 61% were male, 52% had had a prior
stroke or TIA, and the mean CHADS2 stroke risk score was
3.3. A total of 83% were white, 12% were Asian, and there was
a small representation of other racial/ethnic groups. Enrolled
patients came from a broad set of geographic regions: 38%
from Eastern Europe, 19% from Canada/United States, 16%
from Western Europe/similar, 13% from Latin America, and
10% from East Asia (Table 1). Thirty-seven percent of patients
were VKA naïve. Of the 4387 patients taking VKAs before
entry into the trial, 1334 were not taking warfarin (Table 2).
Detailed features of patients participating in the ROCKET AF
trial, stratiﬁed by geographic region, are presented in Table
S1.
Univariable Associations With i-TTR
The overall mean i-TTR was 55.2% (SD 21.3%), and the median
i-TTR was 57.9% (interquartile range [IQR] 43.0% to 70.6%).
The mean time with INR <2 was 29.1%, and the mean time
with an INR >3 was 15.7%. When the deﬁnition of therapeutic
range was expanded to INR 1.8 to 3.5, the mean time in this
therapeutic range was 74.5% (SD 21.8%) and the median was
80.4% (IQR 65.9% to 89.9%). In univariable analysis, multiple
patient features were associated with i-TTR (Tables 1 and 2).
Younger patients, female patients, those with heart failure,
and patients with higher CHADS2 scores had lower mean
i-TTR levels. Asian patients had a mean i-TTR a full 8% lower
than did white patients. Patients who reported light to
moderate alcohol consumption had higher i-TTR levels than
did those who were alcohol abstinent. Prior experience with
warfarin had a notably strong association with i-TTR. Warfarin-
experienced patients had a mean i-TTR of 61.1% compared
with a mean of 47.4% for VKA-naïve patients. Patients who
had previously taken non–warfarin VKAs had a mean i-TTR of
56.9%. Multiple other medications taken at entry into the
study were statistically associated with i-TTR. During follow-
up, 2287 patients had ≥1 hospitalizations. There was no
decrease in mean i-TTR among these hospitalized patients
compared with those avoiding hospitalization during the trial
(data not shown).
Table 1. Mean i-TTR by Baseline Characteristics: Clinical
and Demographic Features
Baseline Variable N (%) i-TTR (Mean %) Univariable P Value
Age, y <0.0001
<73 3487 (50) 53.620.9
≥73 3496 56.821.5
Sex <0.0001
Male 4242 (61) 56.421.2
Female 2741 53.321.3
Race <0.0001
White 5829 (83) 56.320.9
African American 83 (1) 51.921.0
Asian 872 (12) 48.322.4
American
Indian/Alaskan
10 51.219.1
Hawaiian/
Paciﬁc Islander
4 60.112.5
Other 185 (3) 52.621.7
Region <0.0001
East Asia 727 (10) 50.421.4
India 130 (2) 35.923.3
Eastern Europe 2663 (38) 49.721.2
Western
Europe/similar
1088 (16) 63.218.5
South Africa 124 (2) 54.822.1
Latin America 924 (13) 55.220.0
Canada/
United States
1327 (19) 64.118.2
BMI, kg/m2 0.0003
<28 3426 (49) 54.321.4
≥28 3553 56.021.1
Systolic BP, mm Hg 0.0005
<130 2675 (38) 56.820.8
≥130 4300 54.221.5
AF type 0.79
Persistent 5648 (81) 55.121.5
Paroxysmal 1239 (18) 55.320.5
New onset/
diagnosis
96 (1) 56.519.5
Hypertension 0.055
Absence 649 56.721.1
Presence 6334 (91) 55.021.3
Diabetes 0.61
Absence 4230 55.321.3
Presence 2753 (39) 55.021.2
Prior stroke or TIA 0.087
Absence 3338 55.621.2
Presence 3645 (52) 54.821.3
Continued
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Association of Geographic Region and Mean i-TTR
There was remarkable variation in mean i-TTR across
geographic regions, ranging from 36% in the small group of
patients treated in India to 50% for patients treated in Eastern
Europe and East Asia to 63% and 64%, respectively, for
patients treated in Western Europe/similar and Canada/
United States (Figure 1a). Across regions, there were marked
differences in the proportion of patients naïve to VKAs,
ranging from 9.7% of patients in Canada/United States to 53%
in Eastern Europe. In Canada/United States, East Asia, and
Table 1. Continued
Baseline Variable N (%) i-TTR (Mean %) Univariable P Value
Congestive heart failure <0.0001
Absence 2642 59.020.7
Presence 4340 (62) 52.921.2
eGFR (MDRD),15 mL/min per 1.73 m2 0.016
<68 3431 (49) 55.321.2
≥68 3548 55.021.4
Baseline hemoglobin, g/L 0.0052
<10.0 2469 (35) 53.521.5
≥10.0 4510 56.121.1
CAD <0.0001
Absence 5294 54.621.3
Presence 1689 (24) 57.021.0
COPD 0.053
Absence 6259 55.421.3
Presence 719 (10) 53.721.1
PAD 0.047
Absence 6558 55.121.3
Presence 425 (6) 57.220.7
Prior GI bleed <0.0001
Absence 6713 55.021.3
Presence 270 (4) 60.719.3
Liver disease 0.012
Absence 6616 55.321.2
Presence 367 (5) 52.521.9
Alcohol consumption (past 12 mo) <0.0001
Abstinent 4516 (65) 53.221.4
Light 2117 (30) 58.620.5
Moderate 302 (4) 62.119.9
Heavy 47 (1) 48.822.2
CHADS2 score* <0.0001 L
1† 2 33.347.1 0.0015 Q
2 920 (13) 59.319.7
3 3094 (44) 55.121.3
4 1963 (28) 54.321.7
5 852 (12) 53.621.3
6 152 (2) 53.421.5
Continuous predictors are split at median for summarizing TTR but tested as continuous.
Missing data occurred in fewer than 0.2% of records for any variable. Race: for purposes of
testing, race groupswerewhite, Asian, and all others. i-TTR indicates individual patient-level
time in therapeutic range; BMI, body mass index; BP, blood pressure; AF, atrial ﬁbrillation;
TIA, transient ischemic attack; eGFR, estimated glomerular ﬁltration rate; MDRD,
Modiﬁcation of Diet in Renal Disease; CAD, coronary artery disease; COPD, chronic
obstructive pulmonary disease; PAD, peripheral artery disease; GI, gastrointestinal.
*CHADS2: linear (L) and quadratic (Q) models tested.
†CHADS2=1: combined with CHADS2=2 for testing.
Table 2. Mean i-TTR by Baseline Characteristics: Medication
Use
Baseline Variable N
i-TTR
Mean %
Univariable
P Value
Prior VKA experience <0.0001
VKA naïve 2596 (37) 47.422.1
VKA experienced
but warfarin naïve
1334 (19) 56.919.0
Warfarin experienced 3053 (44) 61.119.3
Aspirin <0.0001
Absence 4949 (71) 56.420.8
Presence 2034 52.222.1
ACE inhibitor 0.070
Absence 3223 55.721.3
Presence 3760 (54) 54.821.2
ACE inhibitor or ARB 0.86
Absence 1808 55.321.4
Presence 5175 (74) 55.221.2
Amiodarone <0.0001
Absence 6444 55.721.2
Presence 539 (8) 49.320.6
Digitalis 0.0037
Absence 4278 55.821.3
Presence 2705 (39) 54.321.2
b-Blocker 0.0003
Absence 2411 53.921.8
Presence 4572 (65) 55.821.0
Loop diuretic 0.75
Absence 4577 55.121.3
Presence 2406 (34) 55.321.3
Statin <0.0001
Absence 3968 52.721.6
Presence 3015 (43) 58.420.3
There were no missing data for this Table. i-TTR indicates individual patient-level time in
therapeutic range; VKA, vitamin K antagonist; ACE, angiotensin-converting enzyme; ARB,
angiotensin receptor blocker.
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South Africa, the predominant VKA used before the trial was
warfarin. But, in the remaining regions, many patients who
were VKA experienced were still warfarin naïve (Table 3).
Nonetheless, the qualitative regional patterns of i-TTR across
regions persisted after stratiﬁcation by patients’ experience
with VKAs, although the absolute differences in mean TTR
were modestly reduced. Patients treated in Canada/United
States and Western Europe/similar still had the highest TTRs,
whether patients were experienced with warfarin or com-
pletely VKA naïve. The point estimates were modestly higher
B
C
A
D
E
Figure 1. A, Overall distribution of mean i-TTR (%) by country (gray bars), grouped by region (black bars). B, Distribution of mean i-TTR (%) by
country (gray bars), grouped by region (black bars), for patients naïve to vitamin K antagonist therapy at baseline. C, Distribution of mean i-TTR (%)
by country (gray bars), grouped by region (black bars), for patients experienced with vitamin K antagonist therapy but naïve to warfarin treatment
at baseline. D, Distribution of mean i-TTR (%) by country (gray bars), grouped by region (black bars), for warfarin-experienced patients at baseline.
E, Distribution of overall mean i-TTR (%) by country (gray bars), grouped by region (black bars), excluding the ﬁrst 90 days in the trial. TTR indicates
time in therapeutic range at individual patient level; East Asia: CN, China; HK, Hong Kong; KR, Korea; MY, Malaysia; PH, Philippines; SG, Singapore;
TH, Thailand; TW, Taiwan; Eastern Europe: BG, Bulgaria; CZ, Czech Republic; GR, Greece; HU, Hungary; LT, Lithuania; PL, Poland; RO, Romania; RU,
Russia; TR, Turkey; UA, Ukraine; Western Europe/similar: AT, Austria; AU, Australia; BE, Belgium; CH, Switzerland; DE, Germany; DK, Denmark; ES,
Spain; FI, Finland; FR, France; GB, Great Britain; IL, Israel; IT, Italy; NL, Netherlands; NO, Norway; NZ, New Zealand; SE, Sweden; Latin America: AR,
Argentina; BR, Brazil; CL, Chile; CO, Colombia; MX, Mexico; PE, Peru; VE, Venezuela.
DOI: 10.1161/JAHA.112.000067 Journal of the American Heart Association 5
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for Western Europe/similar versus Canada/United States in
these stratiﬁed analyses (Table 3). Country-level patterns of
mean i-TTR stratiﬁed by warfarin experience at baseline are
presented in Figure 1b through 1d.
By 90 days, patients newly started on warfarin should have
achieved a relatively stable dose. Analyses excluding the ﬁrst
90 days of follow-up resulted in improved regional mean
i-TTRs, particularly in regions with a high proportion of patients
naïve towarfarin. Despite these changes, the regional- (Table 4)
and country-level (Figure 1e) differences persisted. When we
further stratiﬁed these analyses starting at 90 days by patients’
previous exposure to warfarin and VKAs, the regional TTR
patterns were preserved (data not shown).
Multivariable Associations With i-TTR
In multiple linear regression models of mean i-TTR, many
features remained statistically signiﬁcant (Table 5). Particu-
larly strong effects were seen for patients who were VKA
naïve (9.1%, compared with warfarin experienced), women
(9.3%), patients with heart failure (3.2%), patients with
chronic obstructive pulmonary disease (2.9%), patient using
amiodarone at study entry (3.6%), and across categories of
use of alcohol. Even after adjustment for all other signiﬁcant
features (but leaving out race because of collinearity with
region), the effect of geographic region remained remarkable.
With Canada/United States patients as the referent group,
the mean i-TTR was an absolute 8.6% lower for patients in
Eastern Europe, 8.7% lower in East Asia, 4.7% lower in Latin
America, and essentially the same for patients treated in
Western Europe/similar. The small sample of patients in India
had a particularly low average i-TTR. Although there were
several strong determinants of mean i-TTR, the overall
multivariable model R2 was only 16%. By percent of variance
explained (ie, partial R2), the strongest risk factors were VKA
experience (3.7%) and geographic region (4.3%).
Table 3. Regional Mean i-TTR by Prior VKA Experience
N i-TTR, mean % SE Median (25th, 75th) Parameter Estimate P Value
VKA naïve
East Asia 356 47.3 1.1 49 (34, 63) 7.75 0.0005
India 87 32.6 2.5 29 (13, 49) 22.46 <0.0001
Eastern Europe 1414 45.2 0.6 47 (31, 61) 9.90 <0.0001
Western Europe/similar 233 57.8 1.3 62 (48, 72) 2.72 0.25
South Africa 29 46.5 4.8 47 (26, 64) 8.57 0.054
Latin America 348 50.1 1.1 54 (37, 64) 5.00 0.025
Canada/United States 129 55.1 1.8 58 (46, 70) Ref
VKA experienced but warfarin naïve*
East Asia 0
India 20 45.5 5.1 47 (28, 63) 14.72 0.0006
Eastern Europe 619 53.6 0.8 55 (43, 68) 6.53 <0.0001
Western Europe/similar 399 60.1 0.9 63 (50, 73) Ref
South Africa 0
Latin America 293 60.1 1.0 62 (50, 72) 0.08 0.96
Canada/United States 3 64.1 3.8 65 (57, 70)
Warfarin experienced
East Asia 371 53.3 1.1 56 (41, 68) 11.83 <0.0001
India 23 39.9 4.6 42 (27, 52) 25.25 <0.0001
Eastern Europe 630 55.9 0.7 58 (45, 70) 9.16 <0.0001
Western Europe/similar 456 68.7 0.7 70 (60, 79) 3.61 0.64
South Africa 95 57.3 2.1 63 (46, 71) 7.76 <0.0001
Latin America 283 56.4 1.2 59 (45, 71) 8.75 <0.0001
Canada/United States 1195 65.1 0.5 67 (55, 78) Ref
i-TTR indicates individual patient-level time in therapeutic range; VKA, vitamin K antagonist.
*Because there are only 3 patients in this group in North America, Western Europe is used as the reference instead. There are no patients in this group in East Asia or South Africa.
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Variation in i-TTR Across Countries
There was substantial variation in i-TTR across the 45
countries in ROCKET AF, ranging from a mean of 36% to
75%. Substitution of individual countries for geographic
regions in the multiple linear regression model led to an
increase in the overall model R2 from 16% to 19% (Table 6).
Even within regions, there was considerable variability across
countries (Figure 1). Of particular interest, the mean TTR was
47% in China and 38% in Taiwan but 66% in Hong Kong and
64% in Singapore. Ninety-nine percent of the patients in all 4
of these regions were identiﬁed as being of Asian race. When
we substituted patient’s race for patient’s region in the
multivariable model, the overall model R2 deteriorated to
12.8% (Table 7).
Distribution of INR Values and Management of
Test Results
Geographic regional variation in mean i-TTR levels was largely
due to time at INR <2.0 (Figure 2, Table 8). For Canada/United
States patients, the mean time at INR <2.0 was 19.9%. In
contrast, for Eastern European patients, the mean time at INR
<2.0 was 35.2%, and for patients in East Asia, the time at INR
<2.0 was 37.1%. The differences in mean time at INR >3.0
were much smaller and contributed much less to the
differences in i-TTR across regions. If we deﬁne “dangerously”
low as INR <1.7, the regional pattern persisted with patients in
Canada/United States and Western Europe/similar danger-
ously low 8% of the time compared with 19.7% of the time in
Eastern Europe and 18.8% in East Asia. Canada/US and
Western Europe/similar centers were in the “expanded”
therapeutic range of INR 1.8 to 3.5 a mean of 84% and 83%
of the time, respectively. By contrast, patients in East Asia and
Eastern Europe were in this expanded range 70% of the time.
The distributions of INR values conﬁrmed that lower i-TTRs
resulted primarily from subtherapeutic INR levels (Table 8).
The median INR was 2.4 for patients in Canada/United States
and Western Europe/similar but 2.2 for patients in Eastern
Europe and East Asia and 2.3 for patients in Latin America.
The distributions were narrower in Canada/United States and
Western Europe/similar with IQRs of 0.9 INR unit compared
with East Asia and Latin America with IQRs of 1.0 INR unit and
Eastern Europe with an IQR of 1.1 INR units (all P<0.001)
We compared the average number of days between INR
measurements (Figure 3, Table 8). Patients in Canada/United
States and Western Europe had the most frequent INR tests
at an average interval of 19 and 20 days, respectively. By
contrast, patients in Eastern Europe and in East Asia had the
least frequent INR testing with an average interval of 23 days
(P<0.001). We extended this analysis to compare the time to
subsequent INR after an extreme INR value. There was
marked variation in median time to a follow-up INR test after
an INR ≤1.5, from 9 days in Western Europe/similar and
Canada/United States to 26 and 27 days in Eastern Europe
and East Asia, respectively (P<0.001). Similarly, the median
time to a subsequent INR test after an INR ≥4.0 was 7 days in
Western Europe/similar and Canada/United States versus 25
and 23 days in Eastern Europe and East Asia, respectively
(P<0.001). Figure 3 displays the distribution of mean inter-
test intervals as a function of initial INR test result. There is an
inverted “U” pattern seen in all regions but inter-test intervals
were shortest in regions with the highest TTRs, regardless of
initial test result.
Discussion
The linearly interpolated TTR has become a widely accepted
measure of the quality of anticoagulation management.7 In
the ROCKET AF trial, the mean i-TTR for patients assigned to
warfarin was 55%, lower than that reported for other recent
trials of novel anticoagulants,17–19 with a wide range of i-TTR
values. The ROCKET AF trial enrolled patients at particularly
high risk of stroke. One of these stroke risk factors, heart
failure, was associated with an adjusted 3% decrease in
average i-TTR. However, other standard stroke risk factors in
Table 4. Regional Mean i-TTR After First 90 Days of Follow-up
Region N i-TTR, mean % SD Median (25th, 75th) Parameter Estimate P Value
East Asia 677 53.3 21.7 56 (40, 67) 12.52 <0.0001
India 115 39.5 25.2 42 (21, 56) 26.38 <0.0001
Eastern Europe 2462 53.0 21.5 55 (40, 68) 12.82 <0.0001
Western Europe/similar 1019 66.6 17.7 69 (58, 79) 0.76 0.37
South Africa 115 57.6 21.1 59 (46, 74) 8.19 <0.0001
Latin America 875 59.0 20.0 61 (48, 74) 6.84 <0.0001
Canada/United States 1244 65.8 18.7 68 (56, 79) Ref
i-TTR indicates individual patient-level time in therapeutic range.
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AF (ie, prior stroke/TIA, hypertension, and diabetes) had only
modest, if any, univariate effects on i-TTR and none was
selected as a signiﬁcant predictor of i-TTR in our multivariable
model. The 2 strongest determinants of i-TTR (by partial R2)
were not patient comorbidities but rather pretrial experience
with warfarin and geographic site. Patients who were taking
Table 5. Predictors of i-TTR (%) in Warfarin Patients by Multiple Linear Regression Modeling*: Geographical Site of Recruitment
Grouped as Regions
Baseline Characteristic
Multivariable
Parameter Estimate F P Value Partial R2
VKA experience
Warfarin experienced Ref 129.71 <0.0001 0.0374
VKA experienced/warfarin naïve 2.221
VKA naïve 9.138
Region
Canada/United States Ref 49.24 <0.0001 0.0426
Western Europe/similar 0.680
Latin America 4.692
South Africa 8.347
Eastern Europe 8.598
East Asia 8.680
India 20.559
CHF 3.172 37.05 <0.0001 0.0053
Female 9.324 22.74 <0.0001 0.0033
COPD 2.859 13.34 0.0003 0.0019
eGFR, 10 mL/min per 1.73 m2 0.0030
Linear 6.474 11.36 0.0008
Quadratic 0.169 4.77 0.029
Hemoglobin, 2 g/L 0.0029
Linear 8.794 11.17 0.0008
Quadratic 0.276 5.02 0.025
Systolic BP 0.0453 9.39 0.0022 0.0014
BMI 0.0022
Linear 0.677 7.38 0.0066
Quadratic 0.0086 5.13 0.024
Diabetes 1.208 5.77 0.016 0.0008
Alcohol consumption, 12 mo
Abstinent Ref 5.76 0.0006 0.0025
Light 1.772
Moderate 3.012
Heavy 4.921
Medications at entry to the trial
Amiodarone 3.608 16.42 <0.0001 0.0024
Statin 1.682 11.36 0.0008 0.0016
Aspirin 1.111 4.10 0.043 0.0006
i-TTR indicates individual patient-level time in therapeutic range; VKA, vitamin K antagonist; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; eGFR, estimated
glomerular ﬁltration rate; BP, blood pressure; BMI, body mass index.
*For the multivariable model results reported in Table 4a through 4c, n=6961 with 22 subjects omitted because of missing covariate values.
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Table 6. Predictors of i-TTR (%) in Warfarin Patients by Multiple Linear Regression Modeling: Geographical Site of Recruitment
Grouped as Countries
Baseline Characteristic
Multivariable
Parameter Estimate F P Value Partial R2
VKA experience 74.94 <0.0001 0.0217
Warfarin experienced Ref
VKA experienced/warfarin naïve 7.399
VKA naïve 2.153
CHF 2.373 20.19 <0.0001 0.0029
Country 13.73 <0.0001 0.0876
United States Ref
Argentina 1.486
Australia 7.531
Austria 5.945
Belgium 3.014
Brazil 7.721
Bulgaria 9.669
Canada 2.801
Chile 0.302
China 11.081
Colombia 8.315
Czech
Republic
1.641
Denmark 1.548
Finland 4.294
France 1.180
Germany 1.600
Greece 7.210
Hong Kong 3.003
Hungary 3.170
India 21.495
Israel 4.492
Italy 3.818
Korea 14.885
Lithuania 10.173
Malaysia 4.867
Mexico 10.713
Netherlands 0.160
New Zealand 9.905
Norway 4.564
Peru 2.116
Philippines 3.744
Poland 1.884
Romania 10.103
Continued
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warfarin before entry into the trial had an adjusted absolute
9% higher mean i-TTR than those who were VKA naïve.
Interregional mean i-TTR varied by as much as 21%, even after
accounting for patient clinical features and experience with
warfarin. Excluding the small number of patients treated in
India, interregional differences in mean i-TTR still spanned an
absolute 8.7%. Excluding the ﬁrst 90 days of warfarin
treatment, to allow warfarin-naïve patients to become warfa-
rin-experienced, still resulted in large interregional differences
in mean TTR. When country was included in the model instead
Table 6. Continued
Baseline Characteristic
Multivariable
Parameter Estimate F P Value Partial R2
Russia 10.903
Singapore 2.828
South Africa 7.806
Spain 2.821
Sweden 12.009
Switzerland 10.068
Taiwan 20.772
Thailand 3.865
Turkey 16.503
Ukraine 13.930
United Kingdom 6.014
Venezuela 20.635
COPD 2.669 11.91 0.0006 0.0017
Female 6.275 10.24 0.0014 0.0015
Diabetes 1.598 10.22 0.0014 0.0015
BMI 0.0022
Linear 0.744 9.14 0.0025
Quadratic 0.010 6.58 0.010
Systolic BP 0.037 6.28 0.012 0.0009
Hemoglobin, 2 g/L 0.0014
Linear 4.654 3.11 0.078
Quadratic 0.109 0.78 0.38
eGFR, 10 mL/min per 1.73 m2 0.0013
Linear 3.478 3.26 0.071
Quadratic 0.073 0.90 0.34
Alcohol consumption, 12 mo 2.41 0.065 0.0010
Abstinent Ref
Light 0.838
Moderate 1.624
Heavy 5.340
Medications at entry to the trial
Amiodarone 2.616 8.74 0.0031 0.0013
Statin 0.818 2.63 0.11 0.0004
Aspirin 0.619 1.25 0.26 0.0002
i-TTR indicates individual patient-level time in therapeutic range; VKA, vitamin K antagonist; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; BMI, body mass
index; BP, blood pressure; eGFR, estimated glomerular ﬁltration rate.
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of region, the total variance explained increased. Large
regional effects on TTR with similar geographic patterns have
been observed in other recent trials.8,20
Poorer i-TTR primarily reﬂected INR values below 2.0. The
risk of stroke among patients with AF rises steeply the lower
the INR value below 2.0.1 The TTR does not distinguish low
from very low INR values. When we assessed time in
dangerously low INR range (ie, INR <1.7) the regional
differences persisted. When we focused speciﬁcally on the
regional distributions of INR values, we found the lower the
mean i-TTR, the lower the mean INR. For East Asia, in
particular, the IQR of INR values was nearly as narrow as that
for the regions with higher TTRs, suggesting that physicians
were implicitly targeting the low end of the target range of INR
Table 7. Predictors of i-TTR (%) in Warfarin Patients by Multiple Linear Regression Modeling Using Race in Model Rather Than
Region
Baseline Characteristic
Multivariable
Parameter Estimate F P Value Partial R2
VKA experience 239.37 <0.0001 0.0690
Warfarin experienced Ref
VKA experienced/warfarin naïve 11.965
VKA naïve 4.149
CHF 4.942 92.90 <0.0001 0.0132
Female 14.294 37.94 <0.0001 0.0054
Race 20.47 <0.0001 0.0088
White Ref
Black 1.924
Asian 5.919
Other 3.836
eGFR, 10 mL/min per 1.73 m2 0.0048
Linear 11.123 24.26 <0.0001
Quadratic 0.331 14.26 0.0002
Hemoglobin, 2 g/L 0.0043
Linear 15.327 24.42 <0.0001
Quadratic 0.559 15.92 <0.0001
Systolic BP 0.055 13.42 0.0003 0.0019
Alcohol consumption, 12 mo 10.09 <0.0001 0.0044
Abstinent Ref
Light 2.427
Moderate 4.541
Heavy 3.944
COPD 2.305 8.44 0.0037 0.0012
BMI 0.0022
Linear 0.422 2.80 0.095
Quadratic 0.004 1.13 0.29
Diabetes 0.638 1.57 0.21 0.0002
Medications at entry to the trial
Amiodarone 4.395 23.89 <0.0001 0.0034
Statin 2.568 26.35 <0.0001 0.0038
Aspirin 0.782 2.02 0.16 0.0003
i-TTR indicates individual patient-level time in therapeutic range; VKA, vitamin K antagonist; CHF, congestive heart failure; eGFR, estimated glomerular ﬁltration rate; BP, blood pressure;
COPD, chronic obstructive pulmonary disease; BMI, body mass index.
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2.0 to 3.0. The fact that the mean TTR for patients treated in
Hong Kong and Singapore was much higher than the mean
TTR in the remaining countries in East Asia indicates that
medical care practices and not race determine anticoagula-
tion control in this region.21 We found, as well, that regions
with lower TTR values obtained INR tests less frequently.
While follow-up test intervals were shorter the more extreme
the initial INR results, the intervals were still longer in regions
with the lowest TTR. Rose et al have proposed as a quality
indicator the time to follow-up INR after an INR ≤1.5 or
≥4.0.22 We found longer test intervals after such extreme INR
values in regions with lower mean TTRs.
We have used the distinctively large and geographically
diverse cohort of warfarin-treated patients in the ROCKET AF
trial to add to our understanding of the determinants of TTR.
Our study beneﬁts from the high quality of information
captured at study entry, close longitudinal follow-up, and
standardized INR testing with a single type of point-of-care
device. There was comprehensive recording of clinically
scheduled INR test results. As a consequence of the trial
protocol, patients did not go for long periods (ie, >8 weeks)
without an INR test, consistent with guideline recommenda-
tions.14 This is in contrast to usual clinical care where the
distribution of test intervals is broader, adding uncertainty to
the calculation of TTR.23
Our study has limitations. As always, our trial-based results
may not generalize completely to usual clinical care. Our
regional ﬁndings reﬂect the care provided by a limited set of
investigators in any geographic region. As such, we cannot
claim that our ﬁndings are clearly representative of warfarin
management in participating countries. However, it is notable
that the regional pattern of our results is similar to those
reported by the ACTIVE W trial for the countries where both
trials recruited patients.8 In particular, in both the ROCKET AF
and ACTIVE W trials the country with the highest i-TTR was
Sweden and a recent survey of anticoagulation in clinical care
in Sweden reported a mean i-TTR of 74%, nearly identical to
the value of 75% observed in the ROCKET AF trial.24 We
Figure 2. Distribution of times in therapeutic (INR 2.0 to 3.0), low,
and high INR range by geographic region. INR indicates international
normalized ratio.
Figure 3. Inter-INR test interval by value of ﬁrst INR, stratiﬁed by geographic region. INR indicates international normalized ratio; TTR, time in
therapeutic range.
DOI: 10.1161/JAHA.112.000067 Journal of the American Heart Association 13
Geographic Region and Control of TTR on Warfarin Singer et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
cannot account for the resource constraints or cultural norms
underlying different regional practices in managing warfarin.
The widely used Rosendaal measurement of i-TTR uses linear
interpolation to impute daily INR values. Other imputation
approaches might reduce interregional differences in i-TTR.
Ultimately, while i-TTR makes sense as a measure of the
quality of warfarin management, its quantitative relationship
to the net beneﬁt of warfarin therapy is still uncertain.
In conclusion, we found that patient clinical features, such as
heart failure, were signiﬁcant but modest determinants of i-TTR.
Further, wewere able to quantify the reduced control of warfarin
anticoagulation faced by new users of the drug. However, our
most notable ﬁnding was the striking inﬂuence of geographic
region, presumably reﬂecting different levels of aggressiveness
in achieving the INR point target of 2.5, different support
systems to manage warfarin, and different regional barriers to
frequent INR testing and warfarin dose changes. Such geo-
graphic variation in medical practice has become a truism of
health care epidemiology.25,26 While our understanding of the
determinants of i-TTR remains incomplete, it is clear that the
providers of care, and the systems within which they work, have
a profound effect on the quality of anticoagulation.
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